OVdialogue – consider joining our team in the role of Community Champion. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis (mfallis@ovariancanada.org).
Stay tuned for more details, and feel free to share your thoughts below. Let’s make this community even stronger!
Research opportunity: Eligible for PARP inhibitor maintenance therapy but not taking it?
The below information is to inform you of a research study about ovarian cancer maintenance therapy in Canada. This study is conducted by Broadstreet HEOR on behalf of GlaxoSmithKline (also called “GSK”). GSK is a company that discovers and makes vaccines, medicines, and other healthcare products. Ovarian Cancer Canada is committed to driving research forward, and therefore shares relevant research opportunities with those affected by ovarian cancer, where appropriate.
If you have been diagnosed with ovarian cancer,
you may qualify
to take part in a 60-min
virtual interview about your experiences.
Broadstreet HEOR (a Canadian health research company) wants to speak with
adults with ovarian cancer who have received chemotherapy treatment in
Canada and were eligible for PARP inhibitor maintenance therapy afterward but
decided against taking it. Instead, you are being closely monitored by your
doctor and not on any active cancer drugs or treatments.
Anyone who qualifies and participates will receive $80. All information and responses will remain confidential.
To check if you’re eligible, email
Jessica Dunne at ovariancancerstudy@broadstreetheor.com.
Comments
-
Thank you Marianne for informing and posting this.0
